Clinical Trials · NCT05606913
A Study of IBI362 in Participants With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Enrollment
- 731
- Start date
- Jan 2023
- Locations
- 1 site, China
- Primary endpoint
- HbA1c change from baseline at week 28